Bifogade filer
PAXMAN's founder is reducing his shareholding
Kurs
+2,68%
Likviditet
132 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-11-20 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-21 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-21 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-27 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-14 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-19 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2025-05-16 | - | Årsstämma |
| 2025-05-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-08 | - | Extra Bolagsstämma 2025 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2020-05-27 | - | Årsstämma |
| 2020-05-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
PAXMAN announces that the company’s founder and board member Glenn Paxman has sold shares in the company. In connection to this, he has entered a lock-up agreement for 180 days. In total, the transaction amounts to 1,850,000 shares.
Notable among those who increased their ownership are Aktia Fund Management Company Ltd for and on behalf of mutual funds managed by it, Alcur Fonder, Unionen and Grenspecialisten Förvaltning AB. Also the company’s CEO, CFO, and Chairman of the Board further increased their respective holdings.
The CEO Richard Paxman comments:
” Glenn has dedicated over 30 years to the company’s vision since his late wife first lost her hair through chemotherapy treatment. His commitment and passion has helped drive the business to where it is today but now is time he is rewarded for that dedication. One might question why now as we have so much exciting opportunites in the future but the reality is there will never be a perfect time. We have many great milestones ahead of us and we will continue driving impact. I would like to welcome our new and existing shareholders to the group who can now enjoy the future opportunity with my colleagues and I as we drive this business forward.”
Contacts
Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se
About Us
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 6,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK), Houston, Texas (US) and Toronto, Ontario (CA).
The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company’s Certified Adviser.